Health & Fitness
Tue, August 25, 2009Mon, August 24, 2009Sun, August 23, 2009Fri, August 21, 2009Thu, August 20, 2009Wed, August 19, 2009Tue, August 18, 2009Mon, August 17, 2009Sun, August 16, 2009Fri, August 14, 2009Thu, August 13, 2009Wed, August 12, 2009Tue, August 11, 2009Mon, August 10, 2009Fri, August 7, 2009Thu, August 6, 2009Wed, August 5, 2009Tue, August 4, 2009Mon, August 3, 2009Sat, August 1, 2009Fri, July 31, 2009Thu, July 30, 2009Wed, July 29, 2009Tue, July 28, 2009Mon, July 27, 2009Sat, July 25, 2009Fri, July 24, 2009Thu, July 23, 2009Wed, July 22, 2009Tue, July 21, 2009Mon, July 20, 2009Sun, July 19, 2009Fri, July 17, 2009Thu, July 16, 2009Wed, July 15, 2009Tue, July 14, 2009Mon, July 13, 2009Fri, July 10, 2009Thu, July 9, 2009Wed, July 8, 2009Tue, July 7, 2009Mon, July 6, 2009Fri, July 3, 2009Thu, July 2, 2009Wed, July 1, 2009Tue, June 30, 2009Mon, June 29, 2009Fri, June 26, 2009Thu, June 25, 2009Wed, June 24, 2009Tue, June 23, 2009Mon, June 22, 2009Sun, June 21, 2009Fri, June 19, 2009Daxor Corp.: Daxor Embarks on TEAM-HF Multi-Center Heart Failure Treatment Clinical Study
Published in Health and Fitness on Tuesday, July 28th 2009 at 9:13 GMT, Last Modified on 2009-07-28 09:13:12 by Market Wire
NEW YORK, NY--(Marketwire - July 28, 2009) - Daxor Corporation (
The Treatment to Euvolemia (normal blood volume) by Assessment and Measured Blood Volume in Heart Failure or "TEAM-HF" study protocol is a multi-center prospective randomized trial to compare heart failure management strategies based on the current standard of clinical assessment of a patient's blood volume status versus the direct blood volume measurement through the use of Daxor's Blood Volume Analyzer BVA-100. The objectives of TEAM-HF are to determine the decrease of re-hospitalizations, all cause mortalities, cardiovascular mortalities and any improvement in the exercise capacity and quality of life in patients being treated for heart failure when a blood volume analysis is incorporated in their standard diagnosis and treatment. Leading heart failure diagnostic and treatment centers in New York, NY, Pittsburgh, PA, Winston-Salem, NC and Honolulu, HI have already confirmed their participation.
The current Heart Failure Society of America, American College of Cardiology and American Heart Association treatment goals and practice guideline recommendations emphasize that it is critical to evaluate and treat a patient's blood volume to a normal status. Current practices rely solely on various signs and symptoms, along with various surrogate laboratory tests, to determine a patient's blood volume. These surrogate measures are often inaccurate. Daxor's BVA-100 is the only FDA approved instrument which accurately measures a patient's volume status. Recent published studies from Columbia Presbyterian Medical Center have demonstrated that the assessment of a patient's blood volume status is only correct 51% of the time compared to a measured blood volume analysis. The Heart Failure Society of America states that "clinical experience suggests it is difficult to determine that congestion has been adequately treated in many patients."
About 5 million people in the United States have been diagnosed with heart failure and over 300,000 die from it every year. The total estimated direct and indirect cost for treatment of heart failure is approximately $28 billion. In 2005, approximately 37% of all Medicare spending and 50% of inpatient hospital costs were attributed to Medicare beneficiaries being treated for heart failure. Heart failure is a life-threatening condition where the heart muscle cannot pump enough blood to the rest of the body. The most common causes of heart failure are hypertension and coronary heart disease.
"It is our hope that this 300 patient study involving at least 9 medical centers will demonstrate the clinical utility of a blood volume analysis in the treatment of heart failure patients," noted Daxor's Chief Scientific Officer and CEO, Dr. Joseph Feldschuh. Dr. Feldschuh noted that "Previous studies have shown that heart failure patients who have been treated to a normal blood volume, as determined by the BVA-100, had a 100% survival rate over a two year period versus patients who remained volume overloaded who had a 55% death rate. These early published findings are extremely significant, especially since hospitals are now losing their reimbursement for repeated hospitalizations within a 30-day period for the treatment of heart failure."
Unpublished studies from two heart failure centers have shown that some heart failure patients cannot be treated by medications alone, but also require adjunct therapies such as phlebotomy, the removal of excess blood. Therapeutic phlebotomy was once a mainstay for the treatment of heart failure, but is currently only used in limited instances. A Blood Volume Analysis (BVA) can identify which patients may be compromised by inappropriate medical treatments and which would benefit from the removal of excess blood. Without a BVA it is extremely difficult to identify patients who may be anemic and would be harmed from the removal of blood by phlebotomy. The current administration's efforts to improve the efficiency of medical treatments are consistent with the main goals of the TEAM-HF study. If it can be determined that a BVA leads to more appropriate treatments and better outcomes, the BVA-100 may become a standard of care in heart failure.
The TEAM-HF study is anticipated to begin sometime within the third quarter of 2009 and will complete its enrollment and study of patients within 12 months.
Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website [ www.Daxor.com ].
